Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...

The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a ...

Image Source: Zacks Investment Research More on the Latest Nod for JNJ's Spravato as Monotherapy The latest FDA nod for Spravato was based on data from a double-blind, multicenter, placebo ...